Publication | Closed Access

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes

Breast OncologyHepatologyMedicineLiver PhysiologyLapatinib-induced Liver ToxicityPharmacologyPathologyBreast CancerLiver CancerCancer TreatmentOncologyTrastuzumab And/or Taxanes